ures
to the most directly comparable GAAP financial measures in the tables below
include all information reasonably available to Thoratec at the date of
this press release. These tables include adjustments that we can reasonably
predict. Events that could cause the reconciliation to change include
acquisitions and divestitures of business, goodwill and other asset
impairments and sales of marketable equity securities.
The following table includes the GAAP income statement for the three
and six month periods ending in 2008 and 2007.
THORATEC CORPORATION
Condensed Consolidated Statement of Operations
(Unaudited)
(in thousands, except for per share data)
Three Months Ended Six Months Ended
June 28, June 30, June 28, June 30,
2008 2007 2008 2007
Product sales $82,648 $57,333 $147,075 $114,643
Cost of product sales 31,825 23,648 60,415 46,445
Gross profit 50,823 33,685 86,660 68,198
Operating expenses:
Selling, general and
administrative 23,857 19,134 44,493 41,079
Research and development 12,839 10,767 25,358 21,660
Amortization of purchased
intangible assets 3,296 3,143 6,592 6,296
Total operating expenses 39,992 33,044 76,443 69,035
Income (loss) from operations 10,831 641 10,217 (837)
Other income and (expense):
Interest expense (1,131) (1,074) (2,021) (2,142)
Interest income and other 2,281 1,766 4,459 3,953
Income before income taxes 11,981
'/>"/>
SOURCE Thoratec Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Related medicine news :1.
Thoratec Schedules Second Quarter 2008 Conference Call, Webcast2.
Thoratec Schedules First Quarter 2008 Conference Call, Webcast3.
Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation4.
URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device5.
Thoratecs ITC Division Receives FDA Warning Letter6.
Thoratec Schedules Third Quarter Conference Call, Webcast7.
HCA Reports Second Quarter 2008 Results8.
Encision Reports First Fiscal Quarter Results9.
Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million10.
Orchid Cellmark Reports Second Quarter 2008 Financial Results11.
Nutraceutical Reports Q3 Results